$HYOR

HyOrc Corp

CIK:0001070789|SEC Filings

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenue	$ 24,000	$ 0	$ 24,000	$ 150
Gross profit	24,000	0	24,000	150
Other income	0	11,559	0	11,559
Total income	24,000	11,559	24,000	11,709
Administrative and other expenses	374,059	70,972	458,719	94,187
Interest expense	108,092	0	108,092	0
Loan Issuance Costs	11,030	0	11,030	0
(Gain) loss on change in fair value of derivative liability	(17,816)	0	(17,816)	0
Loss on issuance of convertible notes and commitment shares	238,347	0	238,347	0
Total expenses	713,712	70,972	798,372	94,187
Net loss for the period	$ (689,712)	$ (59,413)	$ (774,372)	$ (82,478)

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Statement of Cash Flows [Abstract]
Net loss for the period	$ (689,712)	$ (59,413)	$ (774,372)	$ (82,478)
Amortization of debt discount (non-cash)	20,688		108,092	0
(Gain) loss on change in fair value of derivative liability (non-cash)	(17,816)	0	(17,816)	0
Loss on issuance of convertible notes and commitment shares (non-cash)	238,347	0	238,347	0
Lender legal and transaction costs (non-cash - withheld at closing)			11,030	0
Movements in working capital:
Subscription money advance			55,000	0
Trade payable			80,711	(160,167)
Trade receivable			0	(70)
Intercompany balances			0	0
Net cash provided by (used in) operating activities			(299,008)	(242,716)
Cash flows from investing activities
Investment in subsidiary			0	0
Purchase of plant and equipment			(163,776)	0
Net cash provided by (used in) investing activities			(163,776)	0
Cash flows from financing activities
Proceeds from issuance of convertible notes, net of costs withheld [1]			252,970	0
Proceeds from issuance of common stock			244,308	113,350
Net cash provided by (used in) financing activities			497,278	113,350
Net increase (decrease) in cash and cash equivalents			34,495	(129,366)
Cash and cash equivalents at January 1,			19,417	176,016
Cash and cash equivalents at June 30,	$ 53,912	$ 46,650	$ 53,912	$ 46,650

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current Assets:
Cash and cash equivalents	$ 53,912	$ 19,417
Trade receivable, net	36,541	36,541
Total current assets	90,453	55,958
Plant and equipment	2,483,776	2,320,000
Patents	3,604,558	3,604,558
Goodwill	15,755,344	15,755,344
Investment in subsidiary	0	0
Total non-current assets	21,843,678	21,679,902
TOTAL ASSETS	21,934,131	21,735,860
Current liabilities:
Trade payable	95,711	15,000
Subscription money advance	55,000	0
Convertible notes payable, net of discount	108,092	0
Derivative liability	466,556	0
Total current liabilities	725,359	15,000
Total liabilities	725,359	15,000
Stockholders’ equity:
Common stock	740,035	737,090
Common stock issuable	17,975	0
Additional paid-in capital	29,886,727	29,645,364
Common stock subscribed	105,941	105,941
Accumulated deficit	(9,541,906)	(8,767,534)
Total stockholders’ equity	21,208,771	21,720,860
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 21,934,131	$ 21,735,860